Polyestradiol Phosphate

drug
On this page

Also known as Estradiol phosphate polymerEstradurinFosfato de poliestradiolLEO 114LEO-114Phosphate de polyestradiolPolyest phosPolyestradiol phos phosphate

Summary

Polyestradiol Phosphate (CHEMBL1201477) is an approved small molecule (ATC L02AA02); indicated across 1 condition including neoplasm.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L02AA02
  • Indications: 1 condition

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201477
NamePolyestradiol Phosphate
TypeSmall molecule
Max phase4
ATCL02AA02

Also known as: Estradiol phosphate polymer, Estradurin, Fosfato de poliestradiol, LEO 114, LEO-114, Phosphate de polyestradiol, Polyest phos, Polyestradiol phos phosphate, Polyestradiol phosphate, POLYESTRADIOL PHOSPHATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).